Form 4: Quest Diagnostics SVP Sells Shares Under 10b5-1 Plan

Quest Diagnostics' SVP & Chief Commercial Officer, Mark E. Delaney, sold 7,946 shares of common stock for $187.35 per share after exercising options, as part of a pre-arranged 10b5-1 plan.

Summary

• Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics Inc. (DGX), executed transactions on November 18, 2025.
• Delaney exercised non-qualified stock options to acquire 7,846 shares of common stock at an exercise price of $144.47 per share.
• Additionally, Delaney exercised non-qualified stock options to acquire 100 shares of common stock at an exercise price of $143.33 per share.
• Following these exercises, Delaney sold 7,946 shares of Quest Diagnostics common stock at a price of $187.35 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 sales plan.
• After the reported transactions, Delaney beneficially owns 7,530 shares of common stock directly and 7,484 non-qualified stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While an insider sale reduces direct ownership, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates the negative signal often associated with insider selling. It's a planned liquidity event rather than a reaction to adverse company news.

Positives

• The transactions were executed under a Rule 10b5-1 sales plan, indicating a pre-scheduled sale rather than a reaction to recent company performance.
• The exercise of options demonstrates the reporting person's ability to realize value from previously granted equity compensation.
• The sale price of $187.35 per share is significantly higher than the exercise prices of $144.47 and $143.33, indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned, reduces the reporting person's direct equity stake in the company.
• The sale of 7,946 shares represents a reduction in the direct beneficial ownership of common stock.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a senior executive could be perceived as a slight negative, but the 10b5-1 plan context reduces this impact. It provides liquidity for the executive.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of new material information about the company's performance or outlook. Therefore, it does not provide a strong basis for a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions, rather than this specific insider activity.

Keywords

Quest Diagnostics, DGX, Mark E. Delaney, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, SVP Chief Commercial Officer, Equity Compensation